Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells
about
A Bitter Sweet Symphony: Immune Responses to Altered O-glycan Epitopes in CancerExtended O-GlcNAc on HLA Class-I-Bound Peptides.Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies.Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis.Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responsesBridging innate and adaptive antitumor immunity targeting glycans.Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses.Mumps and ovarian cancer: modern interpretation of an historic association.A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor.Local effects of regulatory T cells in MUC1 transgenic mice potentiate growth of MUC1 expressing tumor cells in vivo.Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses.O-mannosylation of the Mycobacterium tuberculosis adhesin Apa is crucial for T cell antigenicity during infection but is expendable for protection.Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution.What makes MUC1 a tumor antigen?Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.MUC1 as a target antigen for cancer immunotherapy.Designer glycopeptides for cytotoxic T cell-based elimination of carcinomasRetention in endoplasmic reticulum 1 (RER1) modulates amyloid-β (Aβ) production by altering trafficking of γ-secretase and amyloid precursor protein (APP).Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic miceMicrobial carbohydrate depolymerization by antigen-presenting cells: deamination prior to presentation by the MHCII pathwayAn anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells.Synthesis of a Liposomal MUC1 Glycopeptide-Based Immunotherapeutic and Evaluation of the Effect of l-Rhamnose Targeting on Cellular Immune ResponsesEarly in vivo signaling profiles in MUC1-specific CD4(+) T cells responding to two different MUC1-targeting vaccines in two different microenvironmentsState of the art in tumor antigen and biomarker discovery.Natural and Induced Humoral Responses to MUC1.Specificity in cancer immunotherapy.Conserved mycobacterial lipoglycoproteins activate TLR2 but also require glycosylation for MHC class II-restricted T cell activation.Critical role of glycosylation in determining the length and structure of T cell epitopes.Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes.Novel mechanisms underlying the immediate and transient global tolerization of splenic dendritic cells after vaccination with a self-antigen.Immunobiology of human mucin 1 in a preclinical ovarian tumor model.Adaptive immune activation: glycosylation does matter.MUC1 immunotherapy.The sweet side of tumor immunotherapy.MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge.C-type Lectin Receptors for Tumor Eradication: Future Directions.Carbohydrates as T-cell antigens with implications in health and disease.Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer.
P2860
Q26751472-D96EFE95-39F7-43E0-BE9B-FB06904FEBBBQ30356689-1F361281-2AD2-4152-9846-B9F96642BEFFQ33587152-7DAC84AD-AD6C-430E-9D59-6BD9D119F0F3Q33811691-3E8E5003-8225-44C5-8689-6309C2F064E4Q33930126-12762359-F97E-4043-9A67-56540E7DFF9DQ33960021-5E2480A2-DE76-4D3D-9480-DF1565A93AE9Q33961477-613098AB-FCBD-418B-BDD1-1706FCD1C23DQ34001211-BA18217F-1D59-4EB8-9470-C592F55F6F47Q34180646-71757878-8487-46E3-B784-B269D230C948Q34390075-3473E813-852B-42B4-9CF6-22E743001BEFQ34427407-5D3E7F61-A3D7-4D69-BC69-377EF824C325Q34624117-6303AA94-DCD8-4009-BC11-4B6F7BF3C18EQ35018095-E9BC3167-FDD3-453C-8536-B30575920399Q35657628-219E45BE-1C93-4F37-959B-3339289827EDQ35847414-B6836768-9F99-413A-A38A-6FDB8F710E20Q36188575-8289E2C8-A1E2-4DB0-8A4C-690A7E4E50DBQ36221411-3E27AEB3-E579-47FB-BDA1-A432C7B49829Q36238699-0EDCD678-C22E-4F8E-BDF3-D37FFFBB29F5Q36403882-79AEA5AA-B10C-4CA2-A223-265CE289CD87Q36418911-B380D5BB-C28B-446C-A718-DBB5C7B4E41EQ36509312-7446A974-A01A-493C-B410-5EF0702C2D1FQ36516212-FF0C374E-1323-484D-8EAB-AE2E28980D50Q36648430-D3A49580-5EA2-4A2C-856F-0662F74BAB1CQ36815144-76145457-D6AA-4FA5-A74F-FFF553FA3F28Q36866169-FEB5FA11-5F7A-4912-9D46-5FE54AB8A955Q37132800-4CF9AC99-FA0C-4E2F-A31B-D3EE97EA73D2Q37137385-E422BC43-AB19-42D0-AD75-57E446B08B50Q37236636-37A12201-66B3-4F7D-A7B7-E148DF5541F8Q37261047-35CFF9E0-FB22-4480-B955-713F905D02A5Q37384080-FB378728-DA10-4525-9CDC-B8DBD5B6CDD9Q37459645-E0A3DFE3-740E-459E-82BB-F86941818C6DQ37498983-117F6B06-5044-46E2-AECE-B02EF04F3E37Q37527861-BD03B932-688C-40FC-BF95-B3A85EFC8551Q37663706-E9292F27-A0DC-4EFF-9F03-71412B2D757CQ37773241-7377D2C0-7C40-45C5-A089-731A8B2BD966Q38031282-2280A5A0-8048-48F2-AC6E-05D5476F357BQ38091088-194394B3-7326-4DAE-9536-67D8309EF2E3Q38161368-15630164-7D4F-4451-A511-5F2ED910FA0EQ38847198-D38B4F58-CD10-4223-9B5C-192EFCA225E0Q39999722-BC5472D1-FFDE-4D8E-942A-7B2BAFAF5A41
P2860
Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Complex carbohydrates are not ...... ex class II-restricted T cells
@ast
Complex carbohydrates are not ...... ex class II-restricted T cells
@en
type
label
Complex carbohydrates are not ...... ex class II-restricted T cells
@ast
Complex carbohydrates are not ...... ex class II-restricted T cells
@en
prefLabel
Complex carbohydrates are not ...... ex class II-restricted T cells
@ast
Complex carbohydrates are not ...... ex class II-restricted T cells
@en
P2093
P2860
P356
P1476
Complex carbohydrates are not ...... ex class II-restricted T cells
@en
P2093
Anda M Vlad
Franz-Georg Hanisch
Hans Paulsen
Laszlo Otvos
Mare Cudic
Olivera J Finn
Stefan Muller
P2860
P304
P356
10.1084/JEM.20020493
P407
P577
2002-12-01T00:00:00Z